Skip to content

#恒瑞

Today 0 items
Oct 9Fri
  1. biopharmadive.com61

    Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

    Viatris is buying Pacira BioSciences for $1.65 billion, paying $36.50 per share in cash, a 45% premium, to gain the non-opioid pain drugs Exparel and Zilretta for post-surgical and osteoarthritis knee pain. Pacira's two main products booked $692 million in sales in 2025, up about 4% from 2024. The deal is expected to close by the end of 2026, with generics for Exparel likely from early 2030 and Zilretta patents expiring in 2031.

    Why it matters: Large-cap pharma M&A in pain therapeutics, with near-term patent cliffs on the acquired products.

Oct 2Fri
  1. biocentury.com40

    China biopharma still faces a long road to globalization

    Franck Le Deu of KerZheng Ventures argues that Chinese biopharma companies are unlikely to become conventional global competitors by 2030, despite strong science, because the U.S. dominates the profit pool, taking about 53% of world prescription-medicine sales in 2025 and 74% of sales of medicines launched in 2020-24. He weighs Pfizer's Innovent Biologics collaboration worth up to $10.5 billion and China's Five-Year Plan targets, including first-in-class drugs reaching a quarter of the global total and five products exceeding $1 billion in sales by 2030, against barriers like CFIUS and geopolitics. He suggests few will succeed in the Western model, and alternative paths such as affordable innovation outside the U.S. market may define globalization instead.

Oct 1Thu
  1. BioCentury66

    Novo gets shot at weekly obesity pill as Hengrui gets another MNC deal

    Novo Nordisk has in-licensed ex-China rights to a once-weekly oral dual agonist of GLP1R and GIPR from Jiangsu Hengrui Pharmaceuticals for $300 million up front, in one of the largest preclinical deals to date. The compound is intended for obesity, a core therapeutic area Novo Nordisk is building out through a series of deals this year. Hengrui continues its run of MNC partnerships.

    Why it matters: Large preclinical licensing deal with $300 million up front strengthens Novo Nordisk's obesity pipeline.

Sep 30Wed
  2. biopharmadive.com41

    Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill

    Novo Nordisk is paying Hengrui Pharma $300 million up front and up to $2.6 billion in milestones for rights to HRS-1596, a once-weekly oral obesity drug that acts on GLP-1 and GIP. Novo gains rights outside China, Taiwan and nearby territories, aiming to challenge Eli Lilly's Zepbound. Described as Phase 1 ready, the drug has not been tested in humans and could be years from regulatory clearance.

Sep 29Tue
  1. statnews.com43

    STAT+: AstraZeneca invests $2 billion in Summit Therapeutics

    AstraZeneca has invested $2 billion in Summit Therapeutics, according to the headline of a STAT+ report. Separately, Novo Nordisk licensed a once-weekly oral GLP-1/GIP receptor agonist for obesity from Hengrui Pharma, paying $300 million upfront for global rights outside China, with total deal value of $2.6 billion if milestones are met; the drug is ready for Phase 1 development.

    Why it matters: AstraZeneca's $2 billion Summit stake and Novo's $2.6 billion obesity drug deal both move competitive pharma positioning.

  2. biospace.com45

    Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal

    Novo Nordisk is licensing HRS-1596, Hengrui Pharma's once-weekly oral GLP-1R/GIPR dual agonist ready for Phase 1, paying $300 million upfront with the deal worth up to $2.6 billion in milestones plus royalties. The asset is intended for obesity, type 2 diabetes and other metabolic diseases, and China has already cleared it for a Phase 1 study in weight management and T2D. BMO Capital Markets says the deal is unlikely to change near-term competition but once-weekly oral dosing could offer longer-term differentiation.

  3. bsky.app42

    Signal or noise? > Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharma #pharmaceutical

    Novo has agreed a deal worth $2.6 billion with Hengrui for a preclinical GLP-1/GIP drug. Hengrui is described as an in-demand partner in the obesity and metabolic space. No further deal terms or timelines are given.

    Why it matters: Large licensing sum for a preclinical asset signals continued competition for GLP-1/GIP pipeline programs.

Aug 17Mon
  1. fiercepharma.com63

    Sandoz strikes $322M biosimilars deal with Shanghai Henlius

    Sandoz has licensed commercialization rights outside China to three Shanghai Henlius biosimilars in early development: versions of Amgen's Repatha, GSK's Benlysta and Eli Lilly and Merck KGaA's Erbitux, which together generated $6.8 billion in sales last year. Sandoz will pay up to $100.5 million up front and up to $322 million with milestones, and the partnership could expand to 10 biosimilars, growing Sandoz's pipeline from 39 to a potential 46. Henlius retains Chinese rights and continues development and manufacturing.

    Why it matters: Large biosimilar licensing deal targeting three blockbuster biologics amid coming patent expiries.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org